Risk Factors for Liver Function Abnormalities Associated with Tigecycline Combination Therapy in Chinese Patients: A Retrospective Study

Purpose: Tigecycline is a novel tetracycline-class antimicrobial agent in many clinical applications, but many studies have shown that it can easily cause liver function abnormality and even drug-induced liver injury (DILI). Methods: In China, the treatment of various infectious diseases in clinical practice is often carried out by using tigecycline in combination with other antibiotics. Based on this, a total of 95 patients were enrolled in the study cohort to evaluate the incidence of liver function abnormalities caused by tigecycline-based combination treatment plans. Results: Data analysis showed that Group B(tigacycline plus cefoperazone/sulbactam) easily cause liver function abnormalities by increasing AST and ALT levels, and that Group D (Tigacycline plus carbapenems) is prone to liver dysfunction through elevated ALT and TBil levels. Tigecycline plus cefoperazone/sulbactam and tigecycline plus carbapenems is the most likely to cause liver function abnormalities among tigecycline combination therapy of Chinese infectious diseases patients. The logistic regression analysis revealed that APTT and WBC may be risk factors of elevated AST and ALT levels for the combination of tigecycline with cefoperazone/sulbactam ( P 9.5days, which will provide guidance for clinical drug use.